Handelsinvest Investeringsforvaltning Has $293,000 Stock Holdings in Insulet Co. (NASDAQ:PODD)

Handelsinvest Investeringsforvaltning lessened its stake in Insulet Co. (NASDAQ:PODD) by 34.2% during the 1st quarter, Holdings Channel reports. The institutional investor owned 1,710 shares of the medical instruments supplier’s stock after selling 888 shares during the quarter. Handelsinvest Investeringsforvaltning’s holdings in Insulet were worth $293,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its stake in shares of Insulet by 119.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock worth $17,223,000 after purchasing an additional 43,147 shares during the last quarter. Orion Portfolio Solutions LLC increased its stake in shares of Insulet by 276.6% during the 4th quarter. Orion Portfolio Solutions LLC now owns 10,221 shares of the medical instruments supplier’s stock worth $2,069,000 after purchasing an additional 7,507 shares during the last quarter. Asset Management One Co. Ltd. increased its stake in shares of Insulet by 33.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock worth $8,048,000 after purchasing an additional 9,240 shares during the last quarter. Graham Capital Management L.P. increased its stake in shares of Insulet by 689.8% during the 3rd quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock worth $3,683,000 after purchasing an additional 20,171 shares during the last quarter. Finally, Aquila Investment Management LLC acquired a new position in shares of Insulet during the 4th quarter worth $1,302,000.

Analyst Ratings Changes

Several research analysts have recently commented on PODD shares. Redburn Atlantic started coverage on shares of Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 price target on the stock. Raymond James decreased their price objective on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective for the company in a report on Tuesday, May 7th. Jefferies Financial Group upped their price objective on shares of Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Finally, Barclays decreased their price objective on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $239.18.

Insulet Price Performance

Shares of NASDAQ:PODD traded up $1.46 during midday trading on Wednesday, reaching $198.65. 13,701 shares of the company’s stock were exchanged, compared to its average volume of 868,060. The company’s 50 day simple moving average is $184.83 and its two-hundred day simple moving average is $186.20. The firm has a market capitalization of $13.91 billion, a PE ratio of 59.75, a price-to-earnings-growth ratio of 3.63 and a beta of 1.16. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $293.64. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The company had revenue of $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The firm’s revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period last year, the firm earned $0.23 EPS. Equities research analysts expect that Insulet Co. will post 3.11 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other news, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the transaction, the senior vice president now directly owns 14,375 shares of the company’s stock, valued at approximately $2,737,431.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Mark N. Field sold 2,131 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the sale, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mark N. Field sold 1,500 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the sale, the senior vice president now owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The disclosure for this sale can be found here. In the last three months, insiders sold 13,931 shares of company stock valued at $2,636,286. Company insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.